Lynparza is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer. Lynparza may be prescribed for either hormone receptor-positive or -negative cases, depending on previous treatments and other specific factors. Lynparza is also referred to by its drug name, olaparib.
Lynparza is a targeted therapy in a class of drugs called poly (ADP-ribose) polymerase inhibitors, or PARP inhibitors. Lynparza is believed to work by preventing cancer cells from repairing themselves after they have been damaged by chemotherapy.
How do I take it?
Prescribing information states that Lynparza is taken twice daily.
Lynparza comes in tablet and capsule forms.
The FDA-approved label for Lynparza lists common side effects including fatigue, anemia, vomiting, cough, weakness, headache, cold and flu symptoms, muscle and joint pain, strange taste in the mouth, decreased appetite, nausea, upset stomach, and constipation.
Rare but serious side effects listed for Lynparza include fetal harm, pneumonitis (lung inflammation), and myelodysplastic syndrome and acute myeloid leukemia — potentially fatal disorders of the bone marrow.
For more details about this treatment, visit:
Lynparza — AstraZeneca